Trial Profile
Effects of daratumumab in patients with heavily pretreated cardiac immunoglobulin light chain (AL) amyloidosis
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Jan 2017
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Amyloid light-chain amyloidosis
- Focus Therapeutic Use
- 17 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology